Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines

16 May 2017
European Commission

The European Commission has launched an investigation into claims that drug company Aspen Pharma excessively increased prices of five life-saving cancer medicines.

Please click here to read the 'European Commission' news article in full